1. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities 
Craig A. Elmets, MD, Craig L. Leonardi, MD, Dawn M.R. Davis, MD, Joel M. Gelfand, MD, MSCE, Jason Lichten, MD, Nehal N. Mehta, MD, MSCE, April W. Armstrong, MD, MPH, Cody Connor, MD, Kelly M. Cordoro, MD, Boni E. Elewski, MD, Kenneth B. Gordon, MD, Alice B. Gottlieb, MD, PhD, Daniel H. Kaplan, MD, PhD, Arthur Kavanaugh, MD, Dario Kivelevitch, MD, Matthew Kiselica, Neil J. Korman, MD, PhD, Daniela Kroshinsky, MD, MPH, Mark Lebwohl, MD, Henry W. Lim, MD, Amy S. Paller, MD, Sylvia L. Parra, MD, Arun L. Pathy, MD, Elizabeth Farley Prater, MD, Reena Rupani, MD, Michael Siegel, PhD, Benjamin Stoff, MD, MA, Bruce E. Strober, MD, PhD, Emily B. Wong, MD, Jashin J. Wu, MD, Vidhya Hariharan, PhD, Alan Menter, MD 
Journal of the American Academy of Dermatology 
Volume 80, Issue 4, Pages (April 2019)
DOI: /j.jaad
Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

2. Fig 1 Development of PsA relative to duration of skin disease.
From: Christophers E, Barker JN, Griffiths CE, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol. 2010;24(5): PsA, Psoriatic arthritis.
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad )
Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

3. Fig 2 Timing of skin and joint involvement in psoriasis.
Adapted from: Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez Larrea C. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol Aug;30(4):245-50, by permission of Oxford University Press.19
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad )
Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

4. Fig 3
Relative risk of myocardial infarction with age for psoriasis patients. Reproduced with permission from: Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14): Copyright © 2006 American Medical Association. All rights reserved.34
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad )
Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

5. Fig 4
Reprinted from Journal of the American Academy of Dermatology, 76(1). Wu JJ, Guerin A, Sundaram M, et al. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate. pages Copyright © 2017, with permission from Elsevier.40 HR, Hazard ratio; TNFi, tumor necrosis factor inhibitor.
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad )
Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

6. Fig 5
From: Stone NJ, Robinson J, Lichtenstein AH, et al ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (
ASCVD, Atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein cholesterol. ∗Percent reduction in LDL–C can be used as an indication of response and adherence to therapy, but is not in itself a treatment goal. ‡Primary LDL–C ≥160 mg/dL or other evidence of genetic hyperlipidemias, family history of premature ASCVD with onset <55 years of age in a first degree male relative or <65 years of age in a first degree female relative, highsensitivity C-reactive protein >2 mg/L, CAC score ≥300 Agatston units or ≥75 percentile for age, sex, and ethnicity, ankle-brachial index <0.9, or elevated lifetime risk of ASCVD. For complete information on the summary of Statin Initiation Recommendations for the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults please see link A below for 2013 guidelines and B for the updates in 2018 by the ACC/AHA. In the 2018 updated guidelines, psoriasis was deemed an ASCVD risk-enhancing condition favoring early initiation of statin therapy. A: B: and
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad )
Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions